Target intelligence / Profile preview

Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP51) (FKBP5)

Target
FKBP5
Molecular classification
Enzyme, Other
01

Overview

Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP51) is an immunophilin protein that functions as a key co-chaperone for heat shock protein 90 (Hsp90) and plays a critical role in regulating the sensitivity of steroid hormone receptors, particularly the glucocorticoid receptor (GR). Under physiological conditions, FKBP51 binds to the GR-Hsp90 complex, sequestering the receptor in the cytoplasm and reducing its affinity for glucocorticoids, thereby acting as a negative regulator of the hypothalamic-pituitary-adrenal (HPA) axis. Epigenetic modifications, genetic polymorphisms (such as rs1360780), and overexpression of FKBP5 are strongly associated with stress-related psychiatric disorders, including major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and anxiety, as well as chronic pain, metabolic dysfunction, and various cancers. Pharmacological targeting of FKBP51 has emerged as a promising therapeutic strategy, with selective small-molecule inhibitors like SAFit1 and SAFit2 demonstrating efficacy in preclinical models by restoring GR sensitivity, promoting autophagy, and alleviating chronic pain and depressive behaviors. However, drug development faces significant challenges, particularly the need to achieve high selectivity over its highly homologous counterplayer FKBP52, which exerts opposing stimulatory effects on GR activity.

Other names
FKBP51FKBP-51FKBP-5FK506-binding protein 551 kDa FK506-binding protein54 kDa progesterone receptor-associated immunophilinAndrogen-regulated protein 6AIG6PPIase FKBP5Rotamase
02

Mechanism of action

Peptidyl-prolyl cis-trans isomerase inhibition, disruption of the Hsp90 co-chaperone complex, and modulation of glucocorticoid receptor sensitivity.

03

Biological functions

Signal transductionImmune responseOther
04

Disease associations

CancerInflammationNeurodegenerative diseaseOther
05

Safety considerations

Selectivity over FKBP52ImmunosuppressionHPA axis dysregulationAltered metabolic regulationImpaired autophagy
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

FKBP5 mRNA expressionFKBP5 DNA methylationFKBP5 single nucleotide polymorphisms (e.g., rs1360780)Blood FKBP51 protein levels

Beyond the preview

Go deeper on Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP51) (FKBP5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP51) (FKBP5).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call